TipRanks
Reyon Pharmaceutical Co., Ltd. (KR:102460)
:102460
South Korea Market
102460
Reyon Pharmaceutical Co., Ltd.
RESEARCH TOOLSreports

Reyon Pharmaceutical Co., Ltd. (102460) Income Statement

― Followers

Reyon Pharmaceutical Co., Ltd. Income Statement

Last quarter (Q2 2026), Reyon Pharmaceutical Co., Ltd.'s total revenue was ₩35.85B, a decrease of -4.90% from the same quarter last year. In Q2, Reyon Pharmaceutical Co., Ltd.'s net income was ₩-6.80B. See Reyon Pharmaceutical Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
₩ 145.93B₩ 148.30B₩ 151.07B₩ 154.04B₩ 142.80B
Gross Profit
₩ 33.76B₩ 72.79B₩ 78.90B₩ 81.73B₩ 79.44B
Operating Expenses
₩ 65.33B₩ 72.71B₩ 74.87B₩ 72.41B₩ 75.70B
Depreciation and Amortization
₩ 31.79B₩ 6.34B₩ 4.78B₩ 4.53B₩ 4.67B
EBITDA
₩ 228.10M₩ 12.76B₩ 9.01B₩ 13.52B₩ 6.21B
Operating Income
₩ -31.57B₩ 79.26M₩ 4.03B₩ 9.63B₩ 3.74B
Other Income/Expenses
₩ 6.95B₩ 5.08B₩ -1.67M₩ -2.74B₩ 2.11B
Pretax Income
₩ -24.67B₩ 5.16B₩ 4.03B₩ 6.89B₩ 5.84B
Net Income
₩ -29.83B₩ 4.15B₩ 3.58B₩ 7.43B₩ 5.54B
Per Share Metrics
Basic EPS
₩ -1.60K₩ 226.34₩ 195.38₩ 414.51₩ 305.44
Diluted EPS
₩ -1.60K₩ 226.00₩ 195.38₩ 407.00₩ 305.44
Weighted Average Shares Outstanding
 18.59M 18.34M 18.34M 17.75M 17.72M
Weighted Average Shares Outstanding (Diluted)
 18.59M 18.34M 18.34M 17.75M 17.72M
Currency in KRW

Reyon Pharmaceutical Co., Ltd. Earnings and Revenue History